Vascular factors and Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 13, Issue SUPPL. 3, 1999, Pages

  Skoog, Ingmar ^a   Kalaria, Raj N ^b   Breteler, Monique M B ^c  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer disease; Cardiovascular disorders; Cerebrovascular disease; Vascular risk factors

Indexed keywords

APOLIPOPROTEIN E;

ALZHEIMER DISEASE; APOPTOSIS; BLOOD BRAIN BARRIER; CEREBROVASCULAR DISEASE; HUMAN; MULTIINFARCT DEMENTIA; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR;

ALZHEIMER DISEASE; APOLIPOPROTEINS E; APOPTOSIS; BLOOD-BRAIN BARRIER; CEREBROVASCULAR DISORDERS; DEMENTIA, VASCULAR; HUMANS; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 0033202627     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (149)

1. Aharon-Peretz J, Harel T, Revach M, Ben-Haim SA. Increased sympathetic and decreased parasympathetic cardiac innervation in patients with Alzheimer's disease. Arch Neurol 1992;49:919-22.
2. Amar K, Lewis T, Wilcock G, Scott M, Bucks R. The relationship between white matter low attenuation on brain CT and vascular risk factors: a memory clinic study. Age Ageing 1995;24:411-5.
3. Amar K, Wilcock GK, Scott M. The diagnosis of vascular dementia in the light of the new criteria. Age Ageing 1996;25:51-5.
4. Amouyel P, Richard F, Cottel D, Amant C, Codron V, Helbecque N. The deletion allele of the angiotensin I converting enzyme gene as a genetic suscebility factor for cognitive impairment. Neurosci Lett 1996;217: 203-5.
5. Aronson MK, Ooi WL, Morgenstern H, et al. Women, myocardial infarction, and dementia in the very old. Neurology 1990;40:1102-6.
6. Arregui A, Perry E, Rossor M, Tomlinson BE. Angiotensin converting enzyme in Alzheimer's disease: increased activity in caudate nucleus and cortical areas. J Neurochem 1982;82:1490-2.
7. Bader M, Paul M, Fernandez-Alfonso M, Kaling M, Ganten D. Molecular biology and biochemistry of the renin-angiotensin system. In: Swales JD, ed. Textbook of hypertension. Oxford, UK: Blackwell Scientific, 1994:214-32.
8. Barber R, McKeith I, O'Brien J, Perry RH, Ballard C. A comparison of white matter lesions on MRI in dementia with Lewy bodies, Alzheimer's disease, vascular dementia and normal ageing [abstract]. Neurobiol Aging 1998;45:865.
9. 3H]acetylcholine from rat entorhinal cortex in vitro. Brain Res 1989;492:136-43.
10. Barnes NM, Champaneria S, Costall B, Kelly ME, Murphy DA, Naylor RJ. Cognitive enhancing actions of DUP 753 detected in a mouse habituation paradigm. NeuroReport 1990; 1:239-42.
11. Barnes NM, Cheng CH, Costall B, Naylor RJ, Williams TJ, Wischik CM. Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease. Eur J Pharmacol 1991a;20:289-92.
12. Barnes NM, Costall B, Kelly ME, Murphy DA, Naylor RJ. Cognitive enhancing actions of PD 123177 detected in a mouse habituation paradigm. NeuroReport 1991b;2:351-3.
13. Baumbach GL, Heistad DD. Cerebrovascular disease in experimental models of hypertension. In: Swales JD, ed. Textbook of hypertension. Oxford, UK: Blackwell Scientific, 1994:682-90.
14. Behl C, Skutella T, Lezoualc'h F, et al. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 1997;51:535-41.
15. Bendel P, Eilam R. Quantification of ventricular size in normal and spontaneously hypertensive rats by magnetic resonance imaging. Brain Res 1992;574:224-8.
16. Bennett DA, Gilley DW, Wilson RS, Huckman MS, Fox JH. Clinical correlates of high signal lesions on magnetic resonance imaging in Alzheimer's disease. J Neurol 1992;239:186-90.
17. Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG, Svennerholm L. Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol Scand 1990;81: 349-51.
18. Blennow K, Wallin A, Uhlemann C, Gottfries C. White-matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors. Acta Neurol Scand 1991;83:187-93.
19. Breteler MMB. Risk factors for stroke in Alzheimer's disease. In: Leys D, Pasquier F, Scheltens P, eds. Stroke and Alzheimer's disease. The Hague, The Netherlands: Holland Academic Graphics, 1998:59-70.
20. Breteler MMB, van Swieten JC, Bots ML, et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam study. Neurology 1994;44:1246-52.
21. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol 1986;19:253-62.
22. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641-4.
23. Campbell JH, Campbell GR. Pathogenesis of atheroma. In: Swales JD, ed. Textbook of hypertension. Oxford, UK: Blackwell Scientific, 1994:670-81.
24. Claudio L. Utrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. Acta Neuropathol 1996;91:6-14.
25. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
26. Cusi D, Barlassina C, Azzani T, et al. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997;349:1353-7.
27. Davignon J, Bouthillier D, Nestruck AC, Sing CF. Apolipoprotein E polymorphism and atherosclerosis: insight from a study in octogenarians. Trans Am Clin Climatol Assoc 1987;99:100-10.
28. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1-21.
29. DeCarli C, Murohy DG, Tranh M, et al. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology 1995;45: 2077-84.
30. de la Monte SM. Quantitation of cerebral atrophy in preclinical and endstage Alzheimer's disease. Ann Neurol 1989;25:450-9.
31. De Reuck J, Crevits L, De Coster W, Sieben G, vander Eecken H. Pathogenesis of Binswanger chronic progressive subcortical encephalopathy. Neurology 1980;30:920-8.
32. Diaz FJ, Merskey H, Hachinski VC, et al. Improved recognition of leukoaraiosis and cognitive impairment in Alzheimer's disease. Arch Neurol 1991;48:1022-5.
33. Dorheim M-A, Tracey WR, Pollock JS, Grammas P. Nitric oxide synthase activity is elevated in brain microvessels in Alzheimer's disease. Biochem Biophys Res Commun 1994;205:659-65.
34. Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. Acta Neuropathol (Berlin) 1982:57:239-42.
35. Ekeberg O, Kjeldsen SE, Eide I, Leren P. Childhood traumas and psychosocial characteristics of 50-year-old men with essential hypertension. J Psychosom Res 1990;34:643-9.
36. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD. Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils. Nature 1996;382:716-9.
37. Elovaara I, Icén A, Palo J, Erkinjuntti T. CSF in Alzheimer's disease. Studies on blood-brain barrier function and intrathecal protein synthesis. J Neurol Sci 1985;70:73-80.
38. Elovaara I, Seppälä I, Palo J, Sulkava R, Erkinjuntti T. Oligoclonal immunoglobulin bands in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. Acta Neurol Scand 1988;77:397-401.
39. Erkinjuntti T, Hachinski V Dementia post stroke. In: Teasell W, ed. Physical medicine and rehabilitation: state of the art reviews, vol. 7. Philadelphia: Hanley & Belfus, 1993:195-212.
40. Ferrucci L, Guralnik JM, Salive ME, et al. Cognitive impairment and risk of stroke in the older popoulation. J Am Geriatr Soc 1996;44:237-41.
41. Finkel E. Pinning the suspect to the crime in Alzheimer's. Lancet 1996;348:1506.
42. Gale CR, Martyn CN, Cooper C. Cognitive impairment and mortality in a cohort of elderly people. Br Med J 1996;312:608-11.
43. George AE, deLeon MJ, Gentes CI, et al. Leukoencephalopathy in normal and pathologic aging: 1. CT of brain lucencies. Am J Neuroradiol 1986;7:561-6.
44. Glenner GG. Congophilic microangiopathy in the pathogenesis of Alzheimer's syndrome (presenile dementia). Med Hypotheses 1979;5: 1231-6.
45. Hamet P, Richard L, Dam T-V, et al. Apoptosis in target organs of hypertension. Hypertension 1995;26:642-8.
46. Hampel H, Muller-Spahn F, Berger C, Haberl A, Ackenheil M, Hock C. Evidence of blood-cerebrospinal fluid-barrier impairment in a subgroup of patients with dementia of the Alzheimer type and major depression: a possible indicator for immunoacticvation. Dementia 1995;6:348-54.
47. Hardy J, Mann D, Wester P, Winblad B. An integrative hypothesis concerning the pathogenesis and progression of Alzheimer's disease. Neurobiol Aging 1986;7:489-502.
48. Hatazawa J, Yamaguchi T, Ito M, Yamaura H, Matsuzawa T. Association of hypertension with increased atrophy of brain matter in the elderly. J Am Geriatr Soc 1984;32:370-4.
49. Henderson AS. The risk factors for Alzheimer's disease: a review and a hypothesis. Acta Psychiatr Scand 1988;78:257-75.
50. Heyman A, Fillenbaum GG, Welsh-Bohmer KA, et al. Cerebral infarcts in patients with autopsy-proven Alzheimer's disease. CERAD Part XVIII. Neurology 1998;51:159-62.
51. Hofman A, Ott A, Breteler MMB, et al. Atherosclerosis, apolipoprotein E, and the prevalence of dementia and Alzheimer's disease in the Rotterdam study. Lancet 1997;349:151-4.
52. Huang X-C, Richards EM, Sumners C. Mitogen-activated protein kinases in rat brain neuronal cultures are activated by angiotensin type 1 receptors and inhibited by angiotensin II type 2 receptors. J Biol Chem 1996-271:15635-41.
53. Ignatius MJ, Shooter EM, Pitas RE, Mahley RW. Lipoprotein uptake by neuronal growth cones in vitro. Science 1987;236:959-62.
54. Inzitari D, Diaz F, Fox A, et al. Vascular risk factors and leuko-araiosis. Arch Neurol 1987;44:42-7.
55. Johansson BB. Cerebral vascular bed in hypertension and consequences for the brain. Hypertension 1984;6(suppl 3):81-6.
56. Johansson BB. Pathogenesis of vascular dementia: the possible role of hypertension. Dementia 1994;5:174-6.
57. Joseph JA, Shukitt-Hale B, Denisova NA, et al. Long-term dietary strawberry, spinach, or vitamin E supplementation retards the onset of age-related neuronal signal-transduction and cognitive behavioral deficits. J Neurosci 1998;18:8047-55.
58. Kalaria RN. The blood-brain barrier and cerebral microcirculation in Alzheimer's disease. Cerebrovasc Brain Metab 1992;4:226-60.
59. Kalaria RN. Cerebral vessels in ageing and Alzheimer's disease. Pharmacol Ther 1996;72:193-214.
60. Kalaria RN. Apolipoprotein E, arteriosclerosis and Alzheimer's disease. Lancet 1991;349:1174-5.
61. Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999;13(suppl 3):S115-23.
62. Kalaria RN, Golde TE, Cohen ML, Younkin SG. Serum amyloid P in Alzheimer's disease. Implications for dysfunction of the blood-brain barrier. Ann NY Acad Sci 1991;640:145-8.
63. Kalaria RN, Hedera P. Differential degeneration of the cerebral microvasculature in Alzheimer's disease. NeuroReport 1995;6:477-80.
64. Kalaria RN, Hedera P. Beta-amyloid vasoactivity in Alzheimer's disease [letter]. Lancet 1996;347:1492-3.
65. Kalaria RN, Pax AB. Increased collagen content of cerebral microvessels in Alzheimer's disease. Brain Res 1995;705:349-52.
66. Kalmijn S, Feskens EJM, Launer LJ, Stijnen T, Kromhout D. Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 1995;38:1096-102.
67. Kalmijn S, Launer LJ, Lindemans J, Bots JL, Hofman A, Breteler MMB. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam study. Am J Epidemiol 1999;150:283-9.
68. Kalmijn S, Launer LJ, Stolk RP, et al. A prospective study on cortisol, dehydroepiandrosterone sulfate, and cognitive function in the elderly. J Clin Endocrinol Metab 1998;83:3487-92.
69. Kawai M, Kalaria RN, Cras P, et al. Degeneration of vascular muscle cells in cerebral amyloid angiopathy of Alzheimer disease. Brain Res 1993;623:142-6.
70. Kay A, May C, Papadopoulos N, et al. CSF and serum concentration of albumin and IgG in Alzheimer's disease. Neurobiol Aging 1987;8:21-5.
71. Kessler C, Spitzer C, Stausk D, et al. The apolipoprotein E and β-fibrinogen G/A-455 gene ploymorphisms are associated with ischemic stroke involving large-vessel disease. Arteriosclerosis. Thrombosis Vasc Biol 1997;17:2880-4.
72. Kimura T, Hashimura T, Miyakawa T. Observations of microvessels in the brain with Alzheimer's disease by scanning electron microscopy. Jap J Psychiatry Neurol 1991;45:671-6.
73. Kokmen E, Whisnant JP, O'Fallon WM, Chu CP, Beard CM. Dementia after ischaemic stroke: a population based study in Rochester, Minnesota (1960-1984). Neurology 1996;46:154-9.
74. Kuusisto J, Koivisto K, Mykkänen L, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. Br Med J 1997;315:1045-9.
75. Leibson CL, Rocca WA, Hanson VA, et al. Risk of dementia among persons with diabetes mellitus: A population-based cohort study. Am J Epidemiol 1997;145:301-8.
76. Leonardi A, Gandolfo C, Caponetto C, Arata L, Vecchia R. The integrity of the blood-brain barrier in Alzheimer's type and multi-infarct dementia evaluated by the study of albumin and IgG in serum and cerebrospinal fluid. J Neurol Sci 1985;67:253-61.
77. Lethem R, Orrell M. Antioxidants and dementia. Lancet 1997;349: 1189-90.
78. Leys D, Pruvo JP, Parent M, et al. Could Wallerian degeneration contribute to "leuko-araiosis" in subjects free of any vascular disorder? J Neurol Neurosurg Psychiatry 1991;54:46-50.
79. Licandro A, Ferla S, Tavolato B. Alzheimer's disease and senile brains: an immunofluorescence study. Riv Patol Nerv Ment 1983;104:75-87.
80. Longstreth WT, Manolio TA, Arnold A, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The cardiovascular health study. Stroke 1996;27:1274-82.
81. Lotz PR, Ballinger WE Jr, Quisling RG. Subcortical arteriosclerotic encephalopathy: CT spectrum and pathologic correlation. Am J Neuroradiol 1986;7:817-22.
82. Luscher TF. Local relaxant and constricting factors in the vessel wall. In: Swales JD, ed. Textbook of hypertension. Oxford, UK: Blackwell Scientific, 1994:145-59.
83. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-30.
84. Mahley RW. Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease. Israel J Med Sci 1996;32:414-29.
85. Mann DMA, Davies JS, Hawkes J, Yates PO. Immunohistochemical staining of senile plaques. Neuropathol Appl Neurobiol 1982;8:55-61.
86. Mattson MP, Robinson N, Guo Q. Estrogens stabilize mitochondrial function and protect neural cells against the pro-apoptotic action of mutant presenilin-1. NeuroReport 1997;8:3817-21.
87. Meaney MJ, Aitken DH, van Berkel C, Bhatnagar S, Sapolsky RM. Effect of neonatal handling on age-related impairments associated with the hippocampus. Science 1988;239:766-8.
88. Mecocci P, Parnetti L, Reboldi GP, et al. Blood-brain barrier in a geriatric population: barrier function in degenerative and vascular dementia. Acta Neurol Scand 1991;84:210-3.
89. Nag S. Cerebral changes in chronic hypertension: combined permeability and immunohistochemical studies. Acta Neuropathol (Berlin) 1984;62:178-84.
90. Notkola I-L, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E ε4 allele, and Alzheimer's disease. Neuroepidemiology 1998;17:14-20.
91. Olichney JM, Hansen LA, Hofstetter CR, Grundman M, Katzman R, Thal LJ. Cerebral infarction in Alzheimer's disease is associated with severe amyloid angiopathy and hypertension. Arch Neurol 1995;52:702-8.
92. Ott A, Breteler MMB, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam study. Stroke 1997;28:316-21.
93. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MMB. Association of diabetes mellitus and dementia: the Rotterdam study. Diabetologia 1996;39:1392-7.
94. Perlmutter LS, Chui HC. Microangiopathy, the vascular basement membrane and Alzheimer's disease: a review. Brain Res Bull 1990;24:677-86.
95. Perlmutter LS, Myers MA, Barrón E. Vascular basement membrane components and the lesions of Alzheimer's disease: light and electron microscopic analyses. Microsc Res Tech 1994;28:204-15.
96. Perry G, Smith MA, McCann CE, Siedlak SL, Jones PK, Friedland RP. Cerebrovascular muscle atrophy is a feature of Alzheimer's disease. Brain Res 1998;791:63-6.
97. Persson G, Skoog I. A prospective population study of psychosocial risk factors for late-onset dementia. Int J Geriatr Psychiatry 1996;11:15-22.
98. Poirier J, Baccichet A, Dea D, Gauthier S. Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rat. Neuroscience 1993a;55:81-90.
99. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993b;342:697-9.
100. Poirier J, Hess M, May PC, Finch CE. Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Mol Brain Res 1991;11:97-106.
101. Premkumar DRD, Cohen DL, Hedera P, Friedland RP, Kalaria RN. Apolipoprotein E ε4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology in Alzheimer's disease. Am J Pathol 1996;148:2083-95.
102. Román GC. Senile dementia of the Binswanger type. A vascular form of dementia in the elderly. JAMA 1987;258:1782-8.
103. Salerno JA, Murphy GM, Horwitz B, et al. Brain atrophy in hypertension. A volumetric magnetic resonance imaging study. Hypertension 1992;20:340-8.
104. Sapolsky R, Armanini M, Packan D, Tombaugh G. Stress and glucocorticoids in aging. Endocrinol Metabol Clin North Am 1987;16:965-80.
105. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-72.
106. Scheibel AB, Duong T, Tomiyasu U. Denervation microangiopathy in senile dementia, Alzheimer type. Alzheimer Dis Assoc Disord 1987;1:19-37.
107. Scheltens P, Barkhof F, Valk J, et al. White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for a heterogeneity. Brain 1992;115:735-48.
108. Schiffrin EL, Deng LY, Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a β-blocker. J Hypertens 1995;8:229-36.
109. Schmidt R, Fazekas F, Koch M, et al. Magnetic resonance imaging cerebral abnormalities and neuropsychological test performance in elderly hypertensive subjects. A case-control study. Arch Neurol 1995;52:905-10.
110. Skoog I. Risk factors for vascular dementia. A review. Dementia 1994;5: 137-44.
111. Skoog I. The relationship between blood pressure and dementia: a review. Biomed Pharmacother 1997;51:367-75.
112. Skoog I. A review on blood pressure and ischaemic white matter lesions. Dement Geriatr Cogn Cogn Disord 1998a;9(suppl 1):13-9.
113. Skoog I. Arterial hypertension and Alzheimer's disease. In: Leys D, Pasquier F, Scheltens P, eds. Stroke and Alzheimer's disease. The Hague, The Netherlands: Holland Academic Graphics, 1998b:89-100.
114. Skoog I. The interaction between vascular disorders and Alzheimer's disease. In: Iqbal K, Swaab DF, Winblad B, Wisniewski HM, eds. Alzheimer's disease and related disorders: etiology, pathogenesis and therapeutics. Chichester: John Wiley & Sons, 1999:523-30.
115. Skoog I, Hesse C, Aevarsson O, et al. A population study of Apo E genotype at the age of 85: relation to dementia, cerebrovascular disease and mortality. J Neurol Neurosurg Psychiatry 1998a;64:37-43.
116. Skoog I, Hesse C, Fredman P, Andreasson L-A, Palmertz B, Blennow K. Apolipoprotein E in cerebrospinal fluid in 85-year-olds. Relation to dementia, apolipoprotein E polymorphism, cerebral atrophy, and white-matter lesions. Arch Neurol 1997;54:267-72.
117. Skoog I, Lernfelt B, Landahl S, et al. A 15-year longitudinal study on blood pressure and dementia. Lancet 1996;347:1141-5.
118. Skoog I, Nilsson L, Palmertz B, Andreasson L-A, Svanborg A. A population-based study of dementia in 85-year-olds. N Engl J Med 1993;328:153-8.
119. Skoog I, Palmertz B, Andreasson L-A. The prevalence of white matter lesions on computed tomography of the brain in demented and non-demented 85-year-olds. J Geriatr Psychiatry Neurol 1994;7:169-75.
120. Skoog I, Wallin A, Fredman P, et al. A population-study on blood-brain barrier function in 85-year-olds. Relation to Alzheimer's disease and vascular dementia. Neurology 1998b;50:966-71.
121. Slooter AJ, Cruts M, Kalmijn S, et al. Apolipoprotein E and dementia. Risk estimates from a population-based incidence study: the Rotterdam study. Arch Neurol 1998a;55:964-8.
122. Slooter AJ, De Knijff P, Hofman A, et al. Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study. Neurosci Lett 1998b;248:21-4.
123. Slooter AJ, Houwing-Duistermaat JJ, Van Harskamp F, et al. Apolipoprotein E genotype and progression of Alzheimer's disease. The Rotterdam study. J Neurol 1999;246:304-8.
124. Slooter AJ, Tang M, Van Duijn CM, et al. Apolipoprotein E ε4 and the risk of dementia with stroke. A population-based investigation. JAMA 1997;277:818-21.
125. Slooter AJ, Van Duijn CM, Bots ML, et al. Apolipoprotein E genotype, atherosclerosis, and cognitive decline. The Rotterdam study. J Neural Transm 1998c;553:17-29.
126. Smit M, de Knijff P, Rosseneu M, et al. Apolipoprotein E polymorphism in the Netherlands and its effect on plasma lipid and apolipoprotein levels. Hum Genet 1988;80:287-92.
127. Snipes GJ, McGuire CB, Norden JJ, Freeman JA. Nerve injury stimulates the secretion of apolipoprotein E by nonneuronal cells. Proc Natl Acad Sci USA 1986;83:1130-4.
128. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The nun study. JAMA 1997;277:813-7.
129. Soneira CF, Scott TM. Severe cardiovascular disease and Alzheimer's disease: senile plaque formation in cortical areas. Clin Anat 1996;9:118-27.
130. Sparks DL, Hunsaker JC III, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging 1990;11:601-7.
131. Sparks DL, Scheff SW, Liu H, Landers TM, Coyne CM, Hunsaker JC III. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci 1995;131:162-9.
132. Struijker Boudier HAJ. Vascular growth and hypertension. In: Swales JD, ed. Textbook of hypertension. Oxford, UK: Blackwell Scientific, 1994:200-13.
133. Tang M-X, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-32.
134. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996;380:168-71.
135. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
136. Umans JG. Less nitric oxide, more pressure, or the converse? Lancet 1997;349:816.
137. van Bockxmeer FM, Mamotte CDS. Apolipoprotein E4 homozygosity in young men with coronary heart disease. Lancet 1992;340:879-80.
138. Van Gijn G. Leukoaraiosis and vascular dementia. Neurology 1998;51(suppl 3):S3-8.
139. van Swieten JC, Geyskes GG, Derix MM, et al. Hypertension in the elderly is associated with white matter lesions and cognitive decline. Ann Neurol 1991;30:825-30.
140. Vinters HV. Cerebral amyloid angiopathy: a critical review. Stroke 1987;18:311-24.
141. Wang XL, McCredie RM, Wilcken DEL. Common DNA polymorphisms at the lipoprotein lipase gene. Association with severity of coronary artery disease and diabetes. Circulation 1996;93:1339-45.
142. Warsama Jama J, Launer LJ, Witteman JCM, et al. Dietary antioxidants and cognitive function in a population-based sample of older persons. The Rotterdam study. Am J Epidemiol 1996;144:275-80.
143. Wetterling T, Kanitz R-D, Borgis K-J. Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke 1996;27:30-6.
144. Wickelgren I. Tracking insulin to the mind. Science 1998;280:517-51.
145. Wilson PWF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: the Framingham offspring study. JAMA 1994;272:1666-71.
146. Wisniewski HM, Kozlowski PB. Evidence for blood-brain barrier changes in senile dementia of the Alzheimer type (SDAT). Ann NY Acad Sci 1982;396:119-31.
147. Wright JW, Harding JW. Brain angiotensin receptor subtypes in the control of physiological and behavioral responses. Neurosci Biobehav Rev 1994;18:21-53.
148. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 1996;382:685-91.
149. Zubenko GS, Volicer L, Direnfeld LK, Freeman M, Langlais PJ, Nixon RA. Cerebrospinal fluid levels of angiotensin converting enzyme in Alzheimer's disease, Parkinson's disease and progressive supranuclear palsy. Brain Res 1985;328:215-21.